AstraZeneca Forecast, price target & analysts
AstraZeneca Target price 2025 - Analyst rating & recommendation
AstraZeneca Classifications & Recommendation:
AstraZeneca Price Target
| Target Price | £147.90 |
| Price | £136.74 |
| Potential | 8.16% |
| Number of Estimates | 27 |
| 27 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is £147.90. This is 8.16% higher than the current stock price. The highest price target is £193.20 41.29% , the lowest is £66.79 51.16% . | |
| A rating was issued by 33 analysts: 28 Analysts recommend AstraZeneca to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 8.16% . Most analysts recommend the AstraZeneca stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
28 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is £44.6b . This is 3.56% higher than the revenue of the last 12 months(TTM). The highest sales forecast is £46.2b 7.35% , the lowest is £39.9b 7.26% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | £40.0b | 18.03% |
|---|---|---|
| 2025 | £44.6b | 11.33% |
| 2026 | £47.3b | 6.08% |
| 2027 | £50.0b | 5.77% |
| 2028 | £53.4b | 6.88% |
| 2029 | £57.2b | 7.03% |
| 2030 | £61.9b | 8.29% |
| 2031 | £64.8b | 4.66% |
| 2032 | £66.3b | 2.29% |
24 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is £15.9b . This is 17.98% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is £19.7b 46.34% , the lowest is £13.3b 1.11% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | £12.2b | 29.46% |
|---|---|---|
| 2025 | £15.9b | 29.86% |
| 2026 | £17.5b | 10.21% |
| 2027 | £19.2b | 9.64% |
| 2028 | £20.0b | 4.06% |
| 2029 | £22.0b | 10.05% |
| 2030 | £24.9b | 13.08% |
| 2031 | £24.6b | 1.04% |
| 2032 | £25.4b | 3.19% |
EBITDA Margin
| 2024 | 30.60% | 9.68% |
|---|---|---|
| 2025 | 35.70% | 16.65% |
| 2026 | 37.08% | 3.87% |
| 2027 | 38.44% | 3.67% |
| 2028 | 37.42% | 2.65% |
| 2029 | 38.48% | 2.83% |
| 2030 | 40.18% | 4.42% |
| 2031 | 38.00% | 5.43% |
| 2032 | 38.33% | 0.87% |
30 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is £10.8b . This is 54.58% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is £11.3b 63.01% , the lowest is £9.0b 30.04% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | £5.2b | 18.14% |
|---|---|---|
| 2025 | £10.8b | 106.53% |
| 2026 | £12.2b | 13.42% |
| 2027 | £13.6b | 11.49% |
| 2028 | £15.1b | 11.26% |
| 2029 | £16.9b | 11.97% |
| 2030 | £19.3b | 13.90% |
| 2031 | £21.2b | 9.99% |
| 2032 | £21.3b | 0.54% |
Net Margin
| 2024 | 13.01% | 0.09% |
|---|---|---|
| 2025 | 24.14% | 85.55% |
| 2026 | 25.80% | 6.88% |
| 2027 | 27.20% | 5.43% |
| 2028 | 28.32% | 4.12% |
| 2029 | 29.62% | 4.59% |
| 2030 | 31.16% | 5.20% |
| 2031 | 32.75% | 5.10% |
| 2032 | 32.18% | 1.74% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
30 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is £6.93 . This is 55.38% higher than earnings per share in the financial year 2024. The highest EPS forecast is £7.31 63.90% , the lowest is £5.83 30.72% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | £3.33 | 18.09% |
|---|---|---|
| 2025 | £6.93 | 108.11% |
| 2026 | £7.87 | 13.56% |
| 2027 | £8.77 | 11.44% |
| 2028 | £9.76 | 11.29% |
| 2029 | £10.93 | 11.99% |
| 2030 | £12.44 | 13.82% |
| 2031 | £13.69 | 10.05% |
| 2032 | £13.76 | 0.51% |
P/E ratio
| Current | 30.80 | 5.25% |
|---|---|---|
| 2025 | 19.81 | 35.68% |
| 2026 | 17.46 | 11.86% |
| 2027 | 15.66 | 10.31% |
| 2028 | 14.08 | 10.09% |
| 2029 | 12.57 | 10.72% |
| 2030 | 11.04 | 12.17% |
| 2031 | 10.04 | 9.06% |
| 2032 | 9.98 | 0.60% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 5.15 and an P/S ratio of 4.74 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 5.33 | 12.68% |
|---|---|---|
| 2025 | 5.15 | 3.39% |
| 2026 | 4.85 | 5.73% |
| 2027 | 4.59 | 5.46% |
| 2028 | 4.29 | 6.44% |
| 2029 | 4.01 | 6.57% |
| 2030 | 3.70 | 7.65% |
| 2031 | 3.54 | 4.45% |
| 2032 | 3.46 | 2.24% |
P/S ratio
| Current | 4.91 | 16.81% |
|---|---|---|
| 2025 | 4.74 | 3.44% |
| 2026 | 4.47 | 5.73% |
| 2027 | 4.23 | 5.46% |
| 2028 | 3.96 | 6.44% |
| 2029 | 3.70 | 6.56% |
| 2030 | 3.41 | 7.65% |
| 2031 | 3.26 | 4.45% |
| 2032 | 3.19 | 2.24% |
Current AstraZeneca Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Dec 04 2025 |
| Jefferies |
➜
Buy
|
Unchanged | Nov 10 2025 |
| JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Nov 10 2025 |
| Shore Capital |
➜
Buy
|
Unchanged | Nov 06 2025 |
| Berenberg Bank |
➜
Buy
|
Unchanged | Oct 21 2025 |
| JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Oct 13 2025 |
| Shore Capital |
➜
Buy
|
Unchanged | Oct 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Dec 04 2025 |
|
Unchanged
Jefferies:
➜
Buy
|
Nov 10 2025 |
|
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Nov 10 2025 |
|
Unchanged
Shore Capital:
➜
Buy
|
Nov 06 2025 |
|
Unchanged
Berenberg Bank:
➜
Buy
|
Oct 21 2025 |
|
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Oct 13 2025 |
|
Unchanged
Shore Capital:
➜
Buy
|
Oct 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
